Pulmonary TB Clinical Trial
Official title:
Performance Evaluation of Two Diagnostic Technologies for TB Detection Based Upon Breath Testing
This will be a prospective, multicentre study conducted to evaluate the diagnostic accuracy of two TB breath-based technologies independently of the manufacturers. Assay error and failure rates and device operational characteristics will also be assessed during this study. Participants will be enrolled in this study in line with FIND sample banking activities. Results from index tests will not be used to make clinical decisions. Participation in this study will not alter the standard of care.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00933790 -
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
|
Phase 3 | |
Completed |
NCT04645836 -
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
|
N/A | |
Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT03722472 -
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
|
Phase 1 | |
Completed |
NCT03678688 -
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
|
Phase 1/Phase 2 | |
Completed |
NCT00212550 -
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb
|
N/A | |
Completed |
NCT02961569 -
Comparison Between Two Strategies for the Diagnosis of TB
|
N/A | |
Recruiting |
NCT05426720 -
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
|
||
Recruiting |
NCT04264221 -
Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging
|
N/A | |
Active, not recruiting |
NCT05221502 -
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
|
Phase 2 |